426 results on '"Desai, Jayesh"'
Search Results
2. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
3. BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer
4. CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors
5. Bispecific antibodies: advancing precision oncology
6. BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities
7. Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
8. Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours
9. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
10. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies
11. A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
12. A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
13. Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study
14. Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm
15. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours
16. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer
17. Clinical activity in general practice before sarcoma diagnosis: an Australian cohort study.
18. Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN
19. A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours
20. BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
21. New biomarkers for checkpoint inhibitor therapy
22. Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
23. First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)
24. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
25. BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer.
26. Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma.
27. Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion
28. Novel Vaccine Targeting Colonic Adenoma: a Pre-clinical Model
29. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
30. A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours
31. Changing trends in phase 1 oncology clinical trials
32. Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma
33. Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective
34. Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis.
35. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
36. A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers
37. An Update on Immunotherapy for Solid Tumors: A Review
38. Systematic Review of Clinical Outcomes Following Various Treatment Options for Patients with Extraabdominal Desmoid Tumors
39. Personalized Management: Inoperable Gastrointestinal Stromal Tumors
40. Precision oncology using a clinician‐directed, tailored approach to molecular profiling
41. ASO Author Reflections: Immunotherapy for Solid Tumors: A Review
42. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.
43. First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors
44. Advances in our understanding and management of sarcomas - rare bone and soft tissue cancers
45. Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors
46. Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer
47. TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models.
48. Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours.
49. New Drugs in the Management of Sarcoma
50. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.